Authors
Latest:
Dr. Landi Discusses the Importance of Screening in MelanomaMaria Teresa Landi, MD, PhD, senior investigator, Integrative Tumor Epidemiology Branch, National Cancer Institute, discusses the importance of screening in melanoma.
Latest:
DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)DREAMM-7 (NCT04246047) is a global, randomized, open-label, phase III head-to-head trial evaluating the efficacy and safety of BVd triplet vs SoC triplet, DVd, in patients (pts) with RRMM with ≥1 prior line of therapy.
Latest:
Dr. Chavez Mac Gregor on Key Results From SWOG S1207 in HR+/HER2- Breast CancerMariana Chavez Mac Gregor, MD, MSC, discusses key efficacy and safety data from the phase 3 SWOG S1207 trial of everolimus in hormone receptor–positive, HER2-negative breast cancer.
Latest:
Marianne Davies on Managing Immunotherapy Side Effects in Lung CancerMarianne Davies, NP, Assistant Professor of and Clinical Instructor in Nursing, Yale Cancer Center, discusses immune-mediated adverse events in lung cancer.
Latest:
Dr. Nguyen on ABL001 in Patients With CMLMarie Huong Nguyen, MD, assistant professor, Hematology and Oncology, University of Michigan Health System, discusses the safety and efficacy of ABL001 as a potential treatment for patients with chronic myeloid leukemia.
Latest:
Clinical Utility of Emerging Molecular Diagnostics in Breast CancerThe past decade of biomarker research has led to the introduction of several multigene prognostic tests that are now routinely used in clinical decision making to assist the se-lection of patients for adjuvant chemotherapy, and several other tests have emerged with potential clinical utility.
Latest:
Hematology Pipeline: Baby Steps After a Giant LeapA closer look at the hematology pipeline where there are multiple promising studies in progress for hematologic malignancies, including lymphoma, leukemia, and multiple myeloma.
Latest:
Dr. Wood on Family Histories and Genetic CounselingDr. Marie Wood, from the University of Vermont, on Family Histories and Genetic Counseling for Breast and Colorectal Cancers.
Latest:
How Durable Are CAR T-Cell Therapies?The use of chimeric antigen receptor (CAR) T-cell therapies for the treatment of hematologic malignancies is still in its early stages, but when the FDA approved tisagenlecleucel and axicabtagene ciloleucel in 2017, this gave hope to oncologists and patients with some types of leukemia and lymphoma who have exhausted all other options.
Latest:
Future Perspectives on the Treatment of Desmoid TumorsA panel of oncology experts provides insights into the future outlook for desmoid tumor treatment, discussing anticipated developments in the field.
Latest:
Tumor Burden Limits Liver Transplant Feasibility for HCCResearchers have uncovered an upper limit in tumor burden after which there is a lower probability of successfully downstaging patients with hepatocellular carcinoma for liver transplantation.
Latest:
Cemiplimab Monotherapy for First Line Advanced NSCLC Patients With PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-LungDr. Garassino presents 5-year results from the EMPOWER-Lung 1 trial, discussing cemiplimab monotherapy's long-term survival benefits in advanced NSCLC patients with PD-L1 expression ≥50%.
Latest:
Dr. Kremyanskaya on the Need for Disease-Modifying Approaches in MPNsMarina Kremyanskaya, MD, PhD, discusses the need for disease-modifying treatment approaches for patients with myeloproliferative neoplasms.
Latest:
Dr Kremyanskaya on the Use of Cytoreductive Measures in PV and ETMarina Kremyanskaya, MD, PhD, discusses disease and patient characteristics that influence the choice between hydroxyurea and interferon therapy for patients with polycythemia vera or essential thrombocythemia.
Latest:
Dr. Lacouture On Preventing Dermatological Adverse Events in MelanomaMario E. Lacouture, MD, a dermatologist with Memorial Sloan Kettering Cancer Center, explains how providers can manage adverse events that result from melanoma therapies.
Latest:
Dr. Leitao Discusses the Role of HIPEC in Advanced Ovarian CancerMario M. Leitao Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the role of HIPEC in patients with advanced ovarian cancer.
Latest:
Dr. Sznol on the Significance of the Relatlimab/Nivolumab Approval in Metastatic MelanomaMario Sznol, MD, explains the evaluation of efficacy and safety when examining the benefits of new immunotherapy combinations in cancer.
Latest:
Poster Session Highlights: 12th International Lung Cancer CongressA highlight of 3 poster sessions from the 12th International Lung Cancer Congress on August 12, 2011 in Carlsbad, CA.
Latest:
Dr. Morgan on Bulk Reduction Surgery in Ovarian CancerMark A. Morgan, MD, professor of obstetrics and gynecology, University of Pennsylvania, director, Gynecology Oncology for University of Pennsylvania Health Systems, discusses bulk reduction surgery prior to chemotherapy in patients with stage III ovarian cancer.
Latest:
Dr. Rubin on Advantages With Whole-Exome SequencingMark A. Rubin, MD, professor of Pathology and Laboratory Medicine, vice chairman for Experimental Pathology, director, Translational Research Laboratory Services, Weill Cornell Medicine and New-York Presbyterian, discusses the advantages of whole-exome sequencing and how it compares with targeted sequencing.
Latest:
Dr. Schroeder on the Importance of JAK Inhibition in GVHDMark A. Schroeder, MD, discusses the importance of JAK inhibition in graft-versus-host disease (GVHD).
Latest:
Dr. Socinski on the Evolving Paradigm of Targeted Therapy in Lung CancerMark A. Socinski, MD, discusses the evolving paradigm of targeted therapy in lung cancer.
Latest:
Patient Selection and Sequencing of NSCLC ADCsThe panel examines which patient populations might benefit most from treatment with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd). Additionally, they explore potential sequencing strategies for these antibody-drug conjugates in second-line and later treatment settings.
Latest:
NRG1 Fusions in Solid Tumors: The CRESTONE TrialDr Mark Socinski describes the design and findings of the CRESTONE trial.
